6286-65-3

Basic information

• Product Name: 6,7-DIMETHOXY-2-METHYL-3,1-BENZOXAZIN-4-ONE
• Synonyms: 6,7-DIMETHOXY-2-METHYL-3,1-BENZOXAZIN-4-ONE;6,7-dimethoxy-2-methyl-4H-benzo[d][1,3]oxazin-4-one
• CAS NO: 6286-65-3
• Molecular Formula: C₁₁H₁₁NO₄
• Molecular Weight: 221.21
• Mol File: 6286-65-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 182-183 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 377.6°C at 760 mmHg
• Flash Point: 188.2°C
• Appearance: /
• Density: 1.28g/cm³
• Vapor Pressure: 6.65E-06mmHg at 25°C
• Refractive Index: 1.562
• PKA: 1.69±0.20(Predicted)
• CAS DataBase Reference: 6,7-DIMETHOXY-2-METHYL-3,1-BENZOXAZIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-DIMETHOXY-2-METHYL-3,1-BENZOXAZIN-4-ONE(6286-65-3)
• EPA Substance Registry System: 6,7-DIMETHOXY-2-METHYL-3,1-BENZOXAZIN-4-ONE(6286-65-3)

Safety Data

• Hazardous Substances Data: 6286-65-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H11NO4/c1-6-12-8-5-10(15-3)9(14-2)4-7(8)11(13)16-6/h4-5H,1-3H3

Upstream product

• 145352-75-6 2-acetamido-4,5-dimethoxybenzoic acid 
• 73357-18-3 (4,5-dimethoxy-2-nitrophenyl)acetic acid 
• 108-24-7 acetic anhydride 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 20323-74-4 2-carboethoxy-4,5-dimethoxyaniline 
• 100905-33-7 ethyl 2-nitro-4,5-dimethoxybenzoate 

Downstream Products

• 35241-23-7 6,7-dimethoxy-2-methylquinazoline-4(3H)-one 
• 145352-75-6 2-acetamido-4,5-dimethoxybenzoic acid 
• 1772-95-8 6,7-dimethoxy-2-methyl-3-o-tolyl-3H-quinazolin-4-one 
• 127033-39-0 6,7-Dimethoxy-2-((E)-styryl)-3H-quinazolin-4-one 

Relevant articles and documents

New quinazoline-sulfonylurea conjugates: Design, synthesis and hypoglycemic activity

Background: Sulphonylureas are the oldest and commonly used to treat diabetic patients, but its efficacy declines by time. It was reported that quinazoline nucleus exhibits a potent hypoglycemic effect in diabetic animal models. Objective: The current stu

Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1

The ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) was recently shown to promote mineralization of the aortic valve, hence, its inhibition represents a significant target. A quinazoline-4-piperidine sulfamide compound (QPS1) has been described as a specific and non-competitive inhibitor of NPP1. We report herein the synthesis and in vitro inhibition studies of novel quinazoline-4-piperidine sulfamide analogues using QPS1 as the lead compound. Of the 26 derivatives prepared, four compounds were found to have Ki 105 nM against human NPP1.

Distinct novel quinazolinone exhibits selective inhibition in MGC-803 cancer cells by dictating mutant p53 function

The mutant p53 proteins and their corresponding cellular response can be manipulated by novel quinazolinone derivatives 4-8 (a-i) in p53 mutant cancer cells. Of the two most potent compounds, 4a exhibited promising broad-spectrum anti-cancer effects, whereas 6c showed selective and exclusive inhibition activity in p53 mutant cancer cell lines but low toxicity to wild-type p53 cancer cell A375 and normal lung fibroblast WI-38 cells. Furthermore, 6c exhibited a more sophisticated mechanism for cell-destructive response by causing S/G2 phase arrest effect and cell size reduction. Compared with the cellular response of 6b and genetic background of cell lines studied, p53 mutation was found to be the key factor and main target for 6c evoked cell-destructive response. Molecular mechanism studies indicated that p53 phosphorylation and acetylation dual-targeting inhibitor 6c exerted anti-cancer activities with a special mechanism in evoking cell apoptosis by arresting mutant p53 function to trigger the deregulation of Cdk2 caused Bim-mediated apoptosis. To the best of our knowledge, 6c is the first quinazolinone derivative to dictate mutant p53 function for apoptotic cell death.